Varsha Bhatt
Bausch Health Americas, Inc. · Bausch Health Companies
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Varsha Bhatt as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:29 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07428538 · Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)Bausch Health Americas, Inc. · recruiting · Hepatitis · study director
- Ph4NCT05976802 · Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Rectal Foam in Pediatric Patients Aged 5 to 17 Years With Active, Mild to Moderate Distal Ulcerative ColitisBausch Health Americas, Inc. · not yet recruiting · Ulcerative Colitis · study director
- Ph2NCT05098028 · Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell DiseaseBausch Health Americas, Inc. · completed · Sickle Cell Disease · study director
- N/ANCT05027282 · Safety and Effectiveness of the CLEAR + BRILLIANT TOUCH(R) Diode Laser 1440-nm and 1927-nm Combination Wavelength TreatmentBausch Health Americas, Inc. · completed · Photoaging · study director
- Ph2NCT04892706 · Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle GelBausch Health Americas, Inc. · completed · Acne Vulgaris · study director
- Ph4NCT04314375 · Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative ColitisBausch Health Americas, Inc. · recruiting · Ulcerative Colitis · study director
- Ph4NCT03818672 · Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired SubjectsBausch Health Americas, Inc. · terminated · Severe Hepatic Impairment · study director
- N/ANCT03254667 · LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe PsoriasisBausch Health Americas, Inc. · enrolling by invitation · Psoriasis · study director
- Ph4NCT03240809 · An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric SubjectsBausch Health Americas, Inc. · active not recruiting · Psoriasis · study director
- Ph4NCT01846663 · Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic EncephalopathyBausch Health Americas, Inc. · terminated · Hepatic Encephalopathy · study director
- N/ANCT00568997 · 10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used PimecrolimusBausch Health Americas, Inc. · active not recruiting · Atopic Dermatitis · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:29 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 04:29 UTC. The ranking covers the 200 most relevant of 31 PubMed records, and a shared surname and initials can bring in a namesake. All 31 on PubMed
- The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort.Blood Adv · 2018112 citationsRCR 4.1
- Improving attendance at post-emergency department follow-up via automated text message appointment reminders: a randomized controlled trial.Acad Emerg Med · 201558 citationsRCR 3.2
- Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma.Biol Blood Marrow Transplant · 201451 citationsRCR 1.5
- Utilization of initial chemotherapy for newly diagnosed acute myeloid leukemia in the United States.Blood Adv · 201846 citationsRCR 1.7
- 35 citationsRCR 4.4
- Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug.Am J Clin Dermatol · 202233 citationsRCR 4.4
- Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Assessment of Efficacy and Safety in Patients Aged 9 Years and Older.J Drugs Dermatol · 201825 citationsRCR 2.3
- Integrating geriatric assessment and genetic profiling to personalize therapy selection in older adults with acute myeloid leukemia.J Geriatr Oncol · 202223 citationsRCR 1.7
- Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation.Biol Blood Marrow Transplant · 201920 citationsRCR 1.0
- A Multicenter Phase II Trial of Ruxolitinib for Treatment of Corticosteroid Refractory Sclerotic Chronic Graft-Versus-Host Disease.J Clin Oncol · 202416 citationsRCR 2.7